• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Intern Med J . No association of Gaucher Disease with COVID-19-related outcomes: a nationwide cohort study

tetano

Editor, Senior Moderator
Intern Med J


. 2021 Dec 23.
doi: 10.1111/imj.15673. Online ahead of print.
No association of Gaucher Disease with COVID-19-related outcomes: a nationwide cohort study


Ibrahim Demirci[SUP] 1 [/SUP], Tevfik Demir[SUP] 2 [/SUP], Selcuk Dagdelen[SUP] 3 [/SUP], Cem Haymana[SUP] 1 [/SUP], Ilker Tasci[SUP] 4 [/SUP], Aysegul Atmaca[SUP] 5 [/SUP], Derun Ertugrul[SUP] 6 [/SUP], Naim Ata[SUP] 7 [/SUP], Mustafa Sahin[SUP] 8 [/SUP], Serpil Salman[SUP] 9 [/SUP], Ibrahim Sahin[SUP] 10 [/SUP], Rifat Emral[SUP] 8 [/SUP], Ugur Unluturk[SUP] 3 [/SUP], Erman Cakal[SUP] 11 [/SUP], Osman Celik[SUP] 12 [/SUP], Murat Caglayan[SUP] 13 [/SUP], Ilhan Satman[SUP] 14 [/SUP], Alper Sonmez[SUP] 15 [/SUP]



Affiliations

Abstract

Background: It is well documented that patients with chronic metabolic diseases such as diabetes and obesity are adversely affected by the Covid 19 pandemic. However, when the subject is rare metabolic diseases, there is not enough data in the literature.
Aim: To investigate course of COVID-19 among patients with Gaucher disease (GD), the most common lysosomal storage disease.
Methods: Based on the National Health System data, a retrospective cohort of patients with confirmed (PCR positive) COVID-19 infection (n = 149 618) was investigated. The adverse outcomes between patients with GD (n = 39) and those without GD (n = 149 579) were compared in crude and propensity score matched (PSM) groups. The outcomes were hospitalization, the composite of intensive care unit (ICU) admission and/or mechanical ventilation and mortality.
Results: The patients with GD were significantly older and had a higher frequency of hypertension, T2DM, dyslipidemia, asthma or COPD, chronic kidney disease, coronary artery disease, heart failure, and cancer. Although hospitalization rates in Gaucher patients were found to be higher in crude analyzes, the PSM models (model 1, age- and gender-matched; model 2, matched for age, gender, hypertension, T2DM, and cancer) revealed no difference for the outcomes between patients with GD and the general population. According to multivariate regression analyses, having a diagnosis of GD was not a significant predictor for hospitalization (p = 0.241), ICU admission/mechanical ventilation (p = 0.403) or mortality (p = 0.231).
Conclusion: According to our national data, SARS-CoV-2 infection in patients with GD does not have a more severe course than the normal population. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; Coronavirus; Gaucher; Mortality; National; SARS-CoV-2.
 
Back
Top Bottom